The clinical application and research of traditional Chinese medicine formulas (TCMFs) have drawn increasing attention in recent years because of their promising efficacies and minimal side effects, in particularly for multifactorial disorders[@b1]. Although well-accepted and widely used in China, TCMFs are considered as complementary and alternative medicines in many Western countries, mainly due to their complex chemical compositions, unclear effective material basis and action mechanisms, and unstable quality. Hence, more effort should be devoted to in-depth characterization of the chemome of TCMFs to interpret their clinical effects and to establish a comprehensive quality control method to ensure their stable clinical efficacy.

Ultra-performance liquid chromatography (UPLC) coupled with tandem mass spectrometry (MS/MS), *e.g.*, quadrupole-time of flight MS (Q-TOF-MS) or hybrid triple quadrupole-linear ion trap MS (Qtrap-MS), has been a work horse for the measurement of complex TCMFs because of its superiority in terms of separation efficiency, detection sensitivity, and structural characterization potency[@b2][@b3]. Q-TOF-MS has been shown to be intrinsically capable of comprehensively acquiring accurate mass spectral data based on MS[@b1] full scan and MS^E^-based (also known as MS^All^) data-independent acquisition (DIA), indicating promising potential for the global chemical profiling of complex matrices[@b4][@b5][@b6]. However, once obtained, it is a complicated task to completely assign the huge dataset yielded from Q-TOF-MS, and it is even more challenging to exactly assign the fragment ion species generated by MS^E^ to their precursors for the co-eluting components, resulting in a significant barrier for structural identification. Although several post-acquisition data processing approaches, such as the mass defect filter (MDF) technique[@b7] and diagnostic fragment ion (DFI)-based extension strategy[@b5], have been developed to simplify the data processing and to increase the identification confidence, it is still formidable and labor-intensive to achieve the systematic chemical profiling of a complex TCMF.

In response to the shortcomings of the data acquisition and post-acquisition procedures of Q-TOF-MS, information-dependent acquisition (IDA, also known as data-dependent acquisition) of Qtrap-MS and UNIFI, a versatile and automated data processing platform, are adopted in the current study. Qtrap-MS has been widely demonstrated as a powerful apparatus due to its unique ability of simultaneous qualitative and quantitative measurement, usually in an information-dependent manner[@b8][@b9]. Compared with Q-TOF-MS, Qtrap-MS can dramatically increase the data quality, despite its low resolution, by utilizing prior knowledge-based acquisition modes, for instance, the precursor ion (Prec) and predictive multiple reaction monitoring (pMRM) modes. Survey experiments can trigger an enhanced product ion (EPI) scan *via* IDA method to acquire MS/MS data for the selected precursor ions. Moreover, Qtrap-MS can also perform the simultaneous quantitation of numerous analytes with largely different concentrations in complex samples using the scheduled MRM (sMRM) mode without compromising data quality *via* automatic alteration of the dwell time to maintain the desired cycle time[@b10][@b11]. Therefore, Qtrap-MS can act as a complementary qualitative and quantitative tool for Q-TOF-MS. Developed from the core-idea of database searching, the fully automated UNIFI software can accomplish chromatographic peak detection, molecular formula prediction, TCM database retrieval, MS/MS fragment matching, and preliminary chemical characterization almost without human assistance, suggesting that this software dramatically alleviates the workload for mining chemical structures from massive Q-TOF-MS datasets. Several applications of UNIFI have been published[@b12][@b13][@b14][@b15], and the feasibility of UNIFI for chemical profiling of TCMFs, which is an extremely complicated compound pool, has not been systematically proved.

*Baoyuan* decoction (BYD), a well-known TCMF for original Qi vacuity, was initially archived in *Bo Ai Xin Jian* in the Ming dynasty. In modern clinical applications, BYD is a famous TCMF for the treatment of coronary heart disease, aplastic anemia, and chronic renal failure[@b16][@b17]. BYD consists of four famous herbal drugs, i.e., Ginseng Radix et Rhizoma (Chinese name: *Renshen*), Astragali Radix (*Huangqi*), Glycyrrhizae Radix et Rhizoma Praeparata Cum Melle (*Zhigancao*), and Cinnamomi Cortex (*Rougui*). However, the chemical profile of BYD has been scarcely reported, and only 30 flavonoids have been isolated and identified from BYD[@b18][@b19], in contrast to its well-defined pharmacological patterns and clinical benefits.

As a consequence, we aim to propose a systematic strategy by integrating all the merits of UPLC, Q-TOF-MS, Qtrap-MS, and UNIFI software for the rapid and comprehensive qualitative and quantitative characterization of the chemome of BYD. The strategy consists of three steps as illustrated in [Fig. 1](#f1){ref-type="fig"}. The first step is to search for and characterize the primary components of BYD by Q-TOF-MS, in which UNIFI software is used for automated processing of the dataset acquired by the MS^E^ scan mode with the assistance of an in-house library containing all the mass spectrometric information of BYD archived in the literature. The second step is to mine and identify the minor and trace components, for which IDA on UPLC/Qtrap-MS and DIA on UPLC/Q-TOF-MS were performed, in combination with mass fragmentation pathway analyses. Finally, almost all the detected compounds were quantified or relatively quantified by the sMRM mode on a Qtrap-MS. A total of 236 compounds were identified, including 139 saponins, 83 flavonoids, 6 procyanidins, 4 lignans, and 4 diterpenes. Thirty-six representative components were accurately quantified, and 139 components were relatively quantified. These findings provide a facile and practical tool for the rapid and comprehensive qualitative and quantitative profiling and quality control of BYD.

Results
=======

Fragmentation rules and DFIs of saponins and flavonoids
-------------------------------------------------------

Saponins and flavonoids have been identified as the dominant chemical homologues in Ginseng Radix et Rhizoma, Astragali Radix, and Glycyrrhizae Radix et Rhizoma, and thereby serve as the primary chemical classes in BYD. Because attention has been given to the mass fragmentation pathways of ginsenosides, astragalosides, licorice saponins, and flavonoids[@b20][@b21][@b22][@b23][@b24][@b25], the applicability of those cracking rules archived in the literature were verified in this study by employing several representatives, including nine ginsenosides, four astragalosides, ten licorice saponins, and five flavonoids. Moreover, due to the great convenience provided by DFI filtering[@b5] for compound searching and chemical identification, these authentic compounds were also employed to summarize the DFIs for the compounds with the above four chemical categories.

Nine ginsenosides, including protopanaxadiol (PPD)-type (*e.g.*, ginsenosides Rb1, Rb3, Rd), protopanaxatriol (PPT)-type (*e.g.*, ginsenosides Re, Rg1, Rg2), and other rare aglycone skeleton types (*e.g.*, ginsenosides Ro, Rg5, Rk1)[@b24] share similar tandem spectral profiles, and prominent signals were observed as formic acid adduct ions (\[M + HCOO\]^−^) and deprotonated aglycone ions (\[A−H\]^−^) yielded by successive cleavage of sugar residues. Taking ginsenoside Re (PPT-type) as an example, significant signals at *m/z* 991.550 and 945.545 (see [Fig. S1](#S1){ref-type="supplementary-material"}) were assigned to the formic acid adduct ion and the deprotonated molecular ion, respectively, and the DFI for the PPT derivatives was generated at *m/z* 475.379 by successive cleavage of two glucosyl (162 u) and one rhamnosyl (146 u) residues (see [Supplementary Fig. S2A](#S1){ref-type="supplementary-material"}).

Similar to ginsenosides, \[M + HCOO\]^−^, \[M−H\]^−^, and \[A−H\]^−^ ions were afforded as dominant signals in the mass spectral profiles of all four astragalosides. Hence, successive neutral losses of sugar residues and acetyl moieties (if applicable) dominated the fragmentation pathways of astragalosides (see [Supplementary Fig. S2B](#S1){ref-type="supplementary-material"}).

Most saponins from licorice are oleanane-type triterpene saponins (OTSs), *e.g.*, glycyrrhizic acid, licorice-saponins E2, G2, J2, H2, B2, and A3, uralsaponins C and F, and 22*β*-acetoxyglycyrrhizin. Unlike ginsenosides, the deprotonated molecular ions (\[M−H\]^−^) and the deprotonated ion of the diglucuronic acid residue (*m/z* 351.057, B~2~^−^) were prominent signals for the OTSs (see [Supplementary Fig. S2C](#S1){ref-type="supplementary-material"}), whereas formic acid adduct ions were rarely detected, and Y~0~^−^ and Y~1~^−^ ions were occasionally observed[@b22].

Five representative flavonoids, liquiritin apioside, isoliquiritin apioside, calycosin-7-*O*-*β*-d-glucopyranoside, (3 *R*)-(+)-isomucronulatol-2′-*O*-*β*-d-glucopyranoside, and apigenin-6,8-di-*C*-*β*-d-glucopyranoside were used to analyze the mass spectral properties of flavonoids. Similar behaviors were observed for the four flavonoid *O*-glycosides, such as formic acid adduct ions (\[M + HCOO\]^−^) and deprotonated ions (\[M−H\]^−^), deprotonated aglycone ions (\[A−H\]^−^), and some fragments yielded from retro Diels-Alder (RDA) reactions of aglycones[@b23] (see [Supplementary Fig. S4A--D](#S1){ref-type="supplementary-material"}). For instance, liquiritin gave a deprotonated ion at *m/z* 417.119 \[M−H\]^−^ in the MS spectrum, and a characteristic aglycone ion at *m/z* 255.066 through neutral loss of one glucosyl residue (162u) and two abundant fragment ions at *m/z* 135.016 (^1,3^A^−^) and 119.058 (^1,3^B^−^) generated from RDA reaction in the MS/MS spectrum (see [Supplementary Fig. S3](#S1){ref-type="supplementary-material"}). The \[A−H\]^−^ ions were absent for the flavonoid *C*-glycosides due to the stable C-C bond between the aglycone and sugar residue. Instead, neutral losses of (CH~2~O)~n~ (*n* = 2--4) *via* cross-ring cleavage was the fragmentation behavior[@b23]. Taking apigenin-6,8-di-*C*-*β*-d-glucopyranoside as an example, significant distribution occurred for the fragments at *m/z* 473.109 (^0,2^ X ~0α~^−^), 383.077 (^0,3^ X ~0α~∙^0,2^ X ~0β~^−^/^0,2^ X ~0α~∙^0,3^ X ~0β~^−^), and 353.067 (^0,2^ X ~0α~∙^0,2^ X ~0β~^−^)[@b26] corresponding to successive neutral losses of 120.042 u (593.151 → 473.109 or 473.109 → 353.067) and 90.032 u (473.109 → 383.077) in the MS/MS spectrum (see [Supplementary Fig. S4E](#S1){ref-type="supplementary-material"}).

A total of 389 compounds, mainly saponins and flavonoids, have been reported from the four single herbs of BYD, and all of them were included to construct an in-house library. DFIs were proposed for all chemical subtypes based on the fragmentation described above (see [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}). For ginsenosides, some other DFIs found in the literature, such as *m/z* 441.374[@b27], 455.353[@b28], 457.369[@b29], 477.395[@b30], 491.374[@b31], 493.390[@b30], and 507.369[@b32] corresponding to the various aglycones of ginsenosides (see [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}), were included in the ginsenoside-focused screening, in addition to the well-defined DFIs of *m/z* 459.384 and *m/z* 475.379 for PPD- and PPT-type ginsenosides, respectively[@b25]. The \[A−H\]^−^ aglycone ion at *m/z* 489.359 was used as the DFI for searching astragalosides (see [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}). Moreover, the ion at *m/z* 351.057 (B~2~^−^) served as the DFI for mining licorice OTSs because diglucuronic acid substitution occurred for most licorice saponins. For flavonoids that primarily originated from Astragali Radix and Glycyrrhiza Radix, various characteristic aglycone ions such as *m/z* 253.051, 255.066, 267.066, 269.046, 269.081, 271.061, 283.061, 285.061, 289.071, 299.056, 299.093, and 301.110, were used to screen the flavonoids (see [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}), and the neutral losses of 120 u and 90 u served as the diagnostic cleavages for flavonoid *C*-glycosides.

Integrated strategy for the comprehensive chemical characterization of BYD
--------------------------------------------------------------------------

The ingredients in a given matrix can be broadly sub-divided into primary and minor components[@b2]. The primary components usually afford significant LC-MS response, whereas the minor components suffer from extensive co-elution with the primary components and insufficient sensitivity of the adopted method[@b33]. Currently, in-depth profiling the primary constituents is a laborious and time-consuming task, let alone the minor components. Therefore, a systematic strategy was proposed to rapidly and comprehensively screen the chemical constituents in BYD. Firstly, an in-house library that covers most primary components in BYD was constructed, and UNIFI software and Q-TOF-MS were combined to perform automated data mining and structural assignment of the primary constituents. Secondly, several sensitive IDA-mediated methods were applied to the Qtrap-MS domain to extract information belonging to the minor constituents when they were co-eluted with the primary ones, and the mass fragmentation pattern-assisted structural identification was performed by integrating the low-resolution and high-resolution mass spectral information obtained from Qtrap-MS and Q-TOF-MS, respectively.

Automated identification of major components
--------------------------------------------

A versatile data process platform, UNIFI software, was used for the automated processing of the dataset acquired by MS^E^ mode of UPLC/Q-TOF-MS with the assistance of an in-house compound library. Because parameter setting plays a pivotal role in processing outcomes[@b12], the parameters were carefully validated in terms of the accuracy and comprehensiveness of the detection results. The intensity threshold was set at 100cps as a compromise to improve the detection sensitivity while avoiding false positive detection. Regarding peak assignment, the candidate mass-to-charge ratios were automatically matched with the information recorded in the library *via* three important parameters, mass tolerance, adducts/pseudo-molecular ions, and fragment ions, and a candidate compound list was directly outputted. The wide mass tolerance could lead to a higher identification rate, resulting in a higher false detection rate. Thus, 5 ppm was set as a compromise based on the generally acceptable mass error range for accurate analysis. The deprotonated molecular ions (\[M−H\]^−^) together with the adduct ions (\[M + HCOO\]^−^ and \[M + Cl\]^−^) were automatically considered to enhance the selectivity (see [Supplementary Fig. S1](#S1){ref-type="supplementary-material"} and [Fig. S3](#S1){ref-type="supplementary-material"}). Attention was also paid to the fragment ion mapping to estimate the rationality of the candidate compounds, which could allow the fragment ions to be automatically recognized and marked with blue tags in the MS/MS spectra (see [Supplementary Fig. S1](#S1){ref-type="supplementary-material"} and [Fig. S3](#S1){ref-type="supplementary-material"}). The reliability and accuracy of UNIFI for the automated detection and identification of primary compounds in BYD were demonstrated by analyzing 49 authentic compounds, including 32 saponins, 14 flavonoids, and 3 diterpenes, that were isolated from BYD or its constituent herbs. All 49 reference compounds were rapidly and accurately captured by UNIFI. Following the UNIFI-mediated data processing, 113 compounds (see [Fig. 2](#f2){ref-type="fig"} and [Table 1](#t1){ref-type="table"}) were rapidly detected and identified, including 37 ginsenosides, 10 astragalosides, 24 licorice saponins, 28 flavonoids, 6 procyanidins, 4 lignans, and 4 diterpenes.

Minor components characterization
---------------------------------

The detection of minor components was performed by combining Qtrap-MS and Q-TOF-MS. Because comparable sensitivity has been demonstrated between these two analytical platforms[@b34][@b35], most of the components found by various modes of Qtrap-MS were included in the dataset from Q-TOF-MS. Therefore, a workflow was designed to detect and identify the minor components, mainly saponins and flavonoids, in BYD using these two techniques. Firstly, the mass spectral information of the paired precursor-to-product ions afforded by Qtrap-MS guided the extraction of the corresponding ion information by Q-TOF-MS. Then, the proposed DFIs and fragmentation rules, in particular neutral loss (NL) and RDA reactions, were introduced for structural identification.

Saponin- and flavonoid-focused compound screening by Qtrap-MS
-------------------------------------------------------------

As a complementary tool for Q-TOF-MS, Qtrap-MS is advantageous for highlighting the distribution of certain chemical homologues in complex matrices using some targeted screening methods. Based on the aforementioned mass fragmentation patterns of saponins and flavonoids, several survey experiments, such as Prec, pMRM, and MIM[@b36][@b37], were applied to search for saponins and flavonoids in BYD, and an EPI scan was triggered to generate the MS/MS spectra.

The pMRM and MIM modes were combined to screen the saponins in BYD. The pMRM was carried out following a previously published procedure[@b38] with a modified mass range of *m/z* 441--1255 for the Q1 cell. Because some saponins, such as licorice saponins, only exhibit \[M−H\]^−^ ions rather than adduct ions in their MS spectra, an MIM scan was introduced, with an identical mass range as pMRM. As a consequence, a total of 139 saponins were identified out and their MS and MS/MS spectral data are summarized in [Table 1](#t1){ref-type="table"} and [Table S1](#S1){ref-type="supplementary-material"}. All the saponins found with UNIFI were also detected using this method.

The flavonoids in BYD can be divided into aglycones, *O*-glycosides, and *C*-glycosides, and different scan modes were integrated to comprehensively detect the flavonoids. Firstly, a stepped MIM scan was used to record the potential flavonoid aglycones. The minimum molecular weight of the flavonoid skeleton is 222 u, and the molecular weight of a natural flavonoid should be at least 238 u due to the substitution of at least one hydroxy group[@b39]. Therefore, the mass range was set to *m/z* 237--401, corresponding to the substitution of at least one hydroxy group and at most six methoxy groups[@b39]. Consequently, signals at *m/z* 253, 255, 267, 269, 271, 283, 285, 289, 299, and 301 were revealed for the aglycones. Then, the aglycone ions were utilized to screen for flavonoid *O*-glycosides using Prec scan mode, and MIM mode from *m/z* 401--727 was used for flavonoid *C*-glycoside screening because *C*-glycosides contain at most two sugar substituents (2 × 162 u)[@b40]. In total, 12 flavonoid aglycones, 41 flavonoid *O*-glycosides, and 3 flavonoid *C*-glycosides were detected, and the fragment information obtained from EPI was carefully assigned to the corresponding precursor ions. Similar to the saponins, the flavonoids identified by UNIFI were also detected by Qtrap-MS.

Structural identification of minor saponins
-------------------------------------------

Following the introduction of the mass spectral information obtained from Qtrap-MS to the Q-TOF-MS dataset, accurate MS and MS/MS data were assigned to their corresponding compounds, and structural identification was performed. Among the detected saponins, 35 minor saponins were readily assigned as ginsenosides based on their observed aglycone ions, following the manual identification workflow ([Table 1](#t1){ref-type="table"}). Moreover, the successive neutral losses assisted in characterizing the glycan chain, such as cleavages of 162 u, 146 u, and 132 u corresponding to glucosyl, rhamnosyl, and arabinosyl or xylosyl residues, respectively. For example, S~PG~-17 was easily elucidated as a PPT-type ginsenoside from the observed \[A−H\]^−^ ion at *m/z* 475.379, and the fragment ions at *m/z* 799.485 and 637.432 corresponding to the neutral dissociations of one and two glucosyl residues; hence, it was identified as an isomer of Rg1. A total of 32 minor OTSs were rapidly classified and identified according to the summarized DFIs ([Table 1](#t1){ref-type="table"}). For instance, the \[M−H\]^−^ ion of S~GU~-13 was observed at *m/z* 895.396 corresponding to a molecular formula of C~44~H~64~O~19~. The dominant fragment ion at *m/z* 351.057 suggested that two glucuronosyl moieties exist in the structure of S~GU~-13. By matching with the in-house library, S~GU~-13 was tentatively deduced as an isomer of uralsaponin F. The characteristic ion at *m/z* 497.115 in the MS/MS spectra of S~GU~-16, S~GU~-20, and S~GU~-29 indicates the possible presence of a GlcA-GlcA-Rha chain in these OTSs[@b41]. Moreover, seven OTSs that contain single glucuronosyl moiety were also detected and putatively identified by the NL of 176.033 u.

Structural identification of minor flavonoids
---------------------------------------------

Based on our preliminary studies, the flavonoids in BYD can be structurally divided into seven sub-types (see [Supplementary Fig. S5](#S1){ref-type="supplementary-material"}), including flavones, flavanones, isoflavones, chalcones, flavans, isoflavans, and pterocarpans. It was difficult to distinguish the aglycone skeleton types merely by the accurate mass data due to the wide occurrence of isomers. Thus, seven types of flavonoids were further sorted into four groups according to their specific fragmentation rules. Chalcones can be easily transformed to flavanones when encountering a high CE[@b39] and produce the same fragment ions *via* RDA reaction, thus, flavanones and chalcones were classified into group I. The aglycone ions at *m/z* 255.066 (FA-1), 271.061 (FA-2), 269.081 (FA-6), and 285.061 (FA-8), corresponding to different substituents of the flavonoid aglycones, were utilized as DFIs for the detection of compounds in group I. Similarly, isoflavones and flavones afforded identical ^1,3^A^−^ and ^1,3^B^−^ ions; they were therefore assigned to group II. Several DFIs, such as FA-3 at *m/z* 253.051, FA-4 at *m/z* 267.066, FA-5 at *m/z* 269.046, FA-7 at *m/z* 283.061, and FA-10 at *m/z* 299.056 corresponding to diverse aglycones, might be generated by the compounds from group II. The flavans or isoflavans, which could produce \[A−H\]^−^ at *m/z* 289.071 (FA-10) and at *m/z* 301.110 (FA-8) were classified into group III. In addition, the pterocarpan derivatives, which were able to generate a characteristic \[A−H\]^−^ ion at *m/z* 299.0925 (FA-11), were defined as group IV.

Herein, the FA-1-related flavonoids were adopted to illustrate the structural characterization process. A total of 30 compounds were detected as liquiritigenin or isoliquiritigenin derivatives according to the prominent aglycone ion at *m/z* 255.066 and the ^1,3^A^−^ and ^1,3^B^−^ ions at *m/z* 135.016 and 119.058, respectively. Among them, six compounds were unambiguously verified by comparing with reference standards (F~GU~-30, 31, 59, 65, 66, and 83), whereas the identities of the other compounds were tentatively assigned by comparing with the data in the literature.

The sources of the components detected in BYD were proved by parallel measurement of the single herbal medicines (see [Table 1](#t1){ref-type="table"} and [Supplementary Fig. S6](#S1){ref-type="supplementary-material"}).

Quantitative and semi-quantitative analysis of the detected components
----------------------------------------------------------------------

sMRM mode is superior to the common MRM mode when a large number of ion transitions are involved in the quantitative analysis; thus, it was introduced in the present study to simultaneously monitor 175 compounds detected under the quantitation condition. The detailed parameters, including ion transitions, corresponding *t*~R~, and optimal DPs and CEs for the 175 targeted analytes are listed in [Table S2](#S1){ref-type="supplementary-material"}. Based on the comprehensive semi-quantitative analysis of BYD by sMRM mode, 36 representative primary components of them, including 11 flavonoids and 25 saponins, were selected for simultaneous, absolute quantitative analysis. The representative chromatograms of BYD and the extracted ion chromatogram (EIC) of the mixed standards are shown in [Fig. 3](#f3){ref-type="fig"}. All 36 analytes showed good linear regression (*r*^2^ \> 0.999) within the test ranges. The LODs of the compounds were 0.04--23.21 ng/mL, and the LOQs were 0.17--55.25 ng/mL. These data are summarized in [Table S3](#S1){ref-type="supplementary-material"}, indicating that sMRM is sensitive enough to quantitatively determine the large-scale analytes. The relative standard deviation (RSD) values of the intra- and inter-day precision studies were less than 5.23% ([Table S4](#S1){ref-type="supplementary-material"}), indicating that the developed method exhibits satisfactory precision. The recoveries were between 90.68% and 108.92%, with RSDs less than 10%, which meets the quantitative criteria for multi-analytes in complex matrices. Satisfactory repeatability was demonstrated by RSDs of less than 5.01% for all the analytes, and the results of the stability assay suggested that the samples remained stable during measurement. The developed sMRM method was then applied to the simultaneous quantification of 36 analytes in six repeated batches of BYD extracts, and the data are shown in [Table 2](#t2){ref-type="table"}.

Discussion
==========

The efficacy and safety of TCMFs have been demonstrated by the long application history in China and other East Asian countries, such as Korea and Japan. It remains a great challenge to comprehensively understand the chemical composition of TCMFs, although great efforts have been devoted and some state-of-the-art analytical platforms, such as UPLC-Q-TOF-MS and UPLC-Qtrap-MS have been introduced. Attention has been given to the chemical fingerprinting of Ginseng Radix, Astragali Radix, Glycyrrhizae Radix, and Cinnamomi Cortex; however, the chemical composition of BYD has not been thoroughly studied because the decoction process might generate new chemical components through complex chemical reactions[@b42]. In addition, the contents of certain compounds cannot be calculated based on using the mixture ratio of single herbs in a TCMF because drug-drug interactions could occur during the decoction process[@b43][@b44]. For instance, the content of isoflavonoids and astragalosides in BYD was significantly greater than those in the single herbs based on direct comparison of the peak areas; some new compounds, such as ginsenosides S~PG~-1 and S~PG~-24, along with licorice saponins S~GU~-2, S~GU~-25, and S~GU~-39, were revealed in BYD, which are found in trace amounts in Ginseng Radix and Glycyrrhizae Radix but in higher amounts in BYD. Therefore, it is critical and necessary to characterize the chemical profile of TCMFs, even if the constituent herbs have been well defined because the chemical profile of a TCMF cannot be determined by simply pooling all the components from the single herbs.

Because it is a labor-intensive and time-consuming task to assess the quality of TCMFs by comprehensive characterization of their chemical profiles, it is usually feasible to conduct quality control of TCMFs by monitoring tens of components[@b45][@b46]. Although all components captured by UNIFI could be mined by manual data processing, the software has two attractive advantages compared with conventional chemical profiling workflows. First and foremost, the software is sufficiently versatile so that fully automated data processing can be achieved, and all candidate compounds are directly listed following the construction of an in-house library and the setting of the optimum parameters. Only 10 min is required for UNIFI to complete the analysis. Secondly, fragment ion matching can be adopted to improve the accuracy of UNIFI based on the predictive fragmentation pathways. For example, ginsenoside Re and liquiritin (see [Supplementary Figs S1](#S1){ref-type="supplementary-material"} and [S3](#S1){ref-type="supplementary-material"}) were identified by matching not only their molecular ions but also the MS/MS fragment species with the information summarized in the library. Therefore, UNIFI provided a simple, efficient, and accurate method for primary component detection and identification of BYD, indicating a promising option for the chemical analysis and quality control of TCMFs, which are critical to ensure the efficacy and safety of TCMFs.

It may be as important to detect and identify the minor components as it is to detect and identify the primary components when attempting to comprehensively understand the chemical composition of TCMFs. In most cases, the characterization of the minor constituents suffers from their co-elution with the major components and from the insufficient sensitivity of the established method. Despite being useful for the detection and identification of primary compounds, UNIFI extensively neglects minor compounds. The MS and MS/MS signal intensities of the compounds in BYD span three orders of magnitude, resulting in the signals belonging to the minor components being easily submerged by their co-eluting primary components. Therefore, IDA using Qtrap-MS was introduced as a complementary method for MS^E^ by Q-TOF-MS to provide a deeper data mining of the MS^E^ dataset. The Q3 cell of the Qtrap-MS enables rapid switching between conventional radiofrequency/arc (RF/DC) resolving quadrupole mass filter to perform sensitive MRM or NL scanning and linear ion trap (LIT) apparatus to perform EPI scanning[@b47]. In particular, the scan rate of the LIT of 20000 Da/s could fulfill the demands of acquisition of high-quality MS/MS spectral data for all precursor ions that pass the IDA threshold. Although great sensitivity can be obtained by the MS^E^ mode in Q-TOF-MS, all co-eluted precursor ions simultaneously rush into the collision cell to generate fragment ion species which are further transmitted to the TOF chamber of the Q-TOF-MS at the same time due to the wide pass Q1 mode[@b48]. Therefore, the fragment species of all co-eluted compounds share a single MS/MS spectrum and the exact pairing of precursor ions with the corresponding product ion cannot be achieved. Alternatively, the narrow-pass Q1 mode is normally employed for IDA, which affords MS/MS spectra with minimal interference because only precursor ions meeting the preset criteria within the selected narrow *m/z* window (0.6--0.8 Da wide for unit resolution) are transferred to the collision cell to generate product ions. In other words, separate acquisition of the MS/MS spectra is theoretically guaranteed for all Q1 signals detected by pMRM/MIM/Prec mode. Therefore, IDA mode provides useful guidance for the assignment of accurate mass spectral data from sophisticated Q-TOF-MS chromatograms under MS^E^ mode. In the present study, the MIM and pMRM scanning methods were developed to screen potential saponins based on the mass spectrometric behavior obtained with the assistance of several authentic compounds, and the detection of 67 minor saponins, including 35 ginsenosides and 32 OTSs was achieved. MIM and Prec scanning modes were applied to systematically detect flavonoids because of the various DFIs for flavonoids in BYD, resulting in the observation of 56 additional minor flavonoids, including 12 flavonoid aglycones, 41 flavonoid *O*-glycosides, and 3 *C*-glycoside. Based on the stepped MIM/pMRM and MIM/Prec scans, the chromatographic peaks with co-elution phenomenon could be easily distinguished and extracted. For instance, a total of six MS[@b2] spectra were obtained for co-eluted \[M−H\]^−^ ions of *m/z* 807, 823, 837, 955, 1077, and 1209, respectively, by Qtrap-MS at 17.51 min (see [Fig. 4](#f4){ref-type="fig"}), whereas these fragment ions of *m/z* 807.417, 823.412, 837.390, 955.489, 1077.584, and 1209.622 co-existed in a single Q-TOF-MS spectrum. Following the accurate matching of fragment ions with their respective precursor ions in the high-resolution MS spectrum and analyzing all ion species using the proposed fragmentation patterns, the six co-eluted compounds were identified as yunganoside I2 or licorice saponin B2, uralsaponin P, uralsaponin U or uralsaponin N, ginsenoside Ro, ginsenoside Rc, and ginsenoside Ra1.

By combining the rapid and automated identification by UNIFI, the sensitive targeted detection by Qtrap-MS, and the accurate mass measurements by Q-TOF-MS, an LC-MS-based qualitative analysis strategy consisting of two progressive steps was proposed for the rapid, accurate, and global chemical profiling of BYD. The cracking rules and DFIs of the primary chemical homologues in BYD were proposed by employing several representatives, and the mass spectral patterns assisted the structural identification of flavonoids and saponins. For the first step, 113 major components were rapidly identified by automated data-processing with UNIFI software in approximately ten minutes. In particular, the identities of 49 components were confirmed by comparison with the reference standards. In the second step, as many as 123 minor compounds (mainly saponins and flavonoids) were systematically detected from BYD by multiple screening methods based on UPLC/Qtrap-MS and were putatively identified by cross-talking between Qtrap-MS and Q-TOF-MS. Twenty of the compounds were identified as possibly new compounds, including seven licorice saponins (S~GU~-2, S~GU~-5, S~GU~-14, S~GU~-25, S~GU~-27, S~GU~-39, S~GU~-52), seven ginsenosides (S~PG~-1, S~PG~-21, S~PG~-23, S~PG~-24, S~PG~-27, S~PG~-36, S~PG~-58), and six flavonoids (F~AM~-51, F~AM~-55, F~GU~-14, F~GU~-15, F~GU~-32, F~GU~-74). Altogether, 236 compounds were identified from BYD, including 139 saponins, 83 flavonoids, 6 procyanidins, 4 lignans, and 4 diterpenes. Furthermore, the quantitation of 36 primary compounds and the relative quantification of 139 compounds were performed by sMRM using Qtrap-MS for the quality control of BYD.

These findings systematically illustrated the comprehensive chemical composition of BYD and provided the valuable evidences for clarification of the therapeutic material basis and action mechanism of this formula. Saponins and flavonoids were disclosed to be the main components in BYD, and many of them have been reported to have a verity of pharmacological activities on cardiovascular system, which is the main clinical application of BYD. For example, ginsenosides, including Re, Rb1, and Rg1, have the ability to protect the myocardia against injury produced by ischemia and reperfusion[@b49]; astragaloside IV, one of the main active ingredients in Astragali Radix, has the functions of vasodilating effect and protecting the vascular endothelial cells[@b50]; calycosin has the protective action against cardiac injury[@b51]; glycyrrhizin was identified as a thrombin inhibitor *in vitro* and *in vivo*[@b52]; isoliquiritigenin and isoliquiritin, two main active flavonoids of licorice, were reported to have a vasorelaxant effect and be able to decrease the tube formation in vascular endothelial cells[@b53][@b54].

In conclusion, the integrated LC-MS-based strategy provided a meaningful and practical workflow for the rapid, accurate, and comprehensive identification and quantitation of the complicated TCMFs, which will supply valuable references for the further interpretation of their clinical effects, action mechanism, and quality control.

Methods
=======

Materials and reagents
----------------------

All crude materials were collected from a TCM market (Anguo, Hebei, China). Their herbal origins were authenticated by one of the authors (P.F. Tu). Authentic saponins, including ginsenosides Rb1, Rb2, Rb3, Rc, Rd, Re, Rf, Rg1, Rg2, Rg3, Rg5, Rg6, Rh1, Rh2, Rk1, Ro, and F4, pseudoginsenoside F11, notoginsenoside R2, astragalosides II, III, and IV, isoastragaloside II, glycyrrhizic acid, and 18*β*-glycyrrhetic acid were supplied by Chengdu Must Bio-technology Co., Ltd. (Chengdu, Sichuan, China), whilst uralsaponins C and F, 22*β*-acetoxyglycyrrhizin, and licorice-saponins E2, G2, J2, H2, B2, and A3 were kindly provided by Prof. Min Ye (Peking University, Beijing, China)[@b55]. Reference flavonoids, such as (3 *R*)-(+)-isomucronulatol-2′-*O*-*β*-d-glucopyranoside, (3 *R*)-(−)-isomucronulatol-7-*O*-*β*-d-apiofuranosyl(1 → 2)-*β*-d-glucopyranoside, apigenin-6,8-di-*C*-*β*-d-glucopyranoside, neoisoliquiritin, calycosin, calycosin-7-*O*-*β*-d-glupyrancoside, liquiritigenin, liquiritin, isoliquiritigenin, isoliquiritin, isoliquiritin apioside, liquiritin apioside, licuraside, ononin, formononetin, and 7,4′-dihydroxyflavone were previously purified and identified from BYD in our laboratory[@b16][@b17], whereas three diterpenes, i.e., anhydrocinnzeylanol, anhydrocinnzeylanine, and cinnzeylanine were purified and identified from Cinnamomi Cortex[@b56]. The purities of all the reference compounds were determined to be greater than 98% by UPLC-DAD.

Acetonitrile (ACN) and MeOH of LC-MS grade were obtained from Merck (Darmstadt, Germany). LC-MS grade formic acid was obtained from Sigma-Aldrich (Steinheim, Germany). Deionized water was prepared on a Millipore Milli-Q water purification system (Billerica, MA, USA).

Sample preparation
------------------

Pulverized crude materials consisting of Ginseng Radix et Rhizoma (10 g), Astragali Radix (30 g), Glycyrrhizae Radix et Rhizoma Praeparata Cum Melle (10 g), and Cinnamomi Cortex (5 g) were immersed in 550 mL of deionized water for 1 h and were then heated under reflux for 1.5 h two times. Both extractants were combined, filtered, and freeze-dried into powder. Accurately weighed lyophilized powder (0.2 g) was thoroughly suspended in ten volumes of deionized water. After centrifugation at 9,600 rpm for 10 min, a 500 μL aliquot of the supernatant was loaded onto a preconditioned Phenomenex Strata-X SPE column (500 mg/5 mL, Torrance, CA, USA) and successively eluted with 6 mL of water and 6 mL of MeOH. The MeOH effluent was concentrated to dryness under reduced pressure, reconstituted in 1 mL of MeOH, and filtered through a 0.22-μm membrane prior to LC-MS analysis. The injection volume was 0.6 μL. Additionally, extract samples of the four constituent herbs of BYD were prepared in parallel.

A stock solution (1 mg/mL) of each reference sample was obtained by dissolving accurately weighed compound in MeOH. All solutions were maintained at −20 °C prior to use.

UPLC/Q-TOF-MS conditions
------------------------

The Waters ACQUITY UPLC system was connected to an Xevo-G2 Q-TOF mass spectrometer *via* an electrospray ionization (ESI) interface (Milford, MA, USA). Waters Empower software (Version 2) was used for apparatus synchronization and data acquisition and processing. Chromatographic separations were conducted on a Waters CORTECS UPLC C~18~ column (1.6 μm, 2.1 × 100 mm, Milford, MA, USA). The mobile phase consisting of 0.05% aqueous formic acid (A) and ACN containing 0.05% formic acid (B) was programmed in gradient as follows: 0.0--2.0 min, 2--15% B; 2.0--12.0 min, 15--25% B; 12.0--22.0 min, 25--40% B; 22.0--30.0 min, 40--60% B; 30.0--37.0 min, 60--100% B; 37.0--39.0 min, 100% B; 39.0--39.01 min, 100--2% B; and 39.01--45.0 min, 2% B. The flow rate was 0.4 mL/min. The temperatures of the column oven and auto-sampler were maintained at 35 °C and room temperature, respectively.

Leucine-enkephalin was used as the lock mass compound for accurate mass calibration. All MS^E^ data were acquired with negative polarity. The ion-source parameters were set as follows: source temperature, 110 °C; desolvation temperature, 450 °C; desolvation gas (N~2~), 650 L/h, and nebulizer gas, 20 L/h. Two separate runs were conducted using the optimal compound-dependent parameters for flavonoids and saponins. For the former, parameters were set as follows: the capillary voltage, −2.03 kV; cone voltage, −10 V; collision energy (CE), −6 eV for MS and −15 to −55 eV for MS/MS, respectively; and MS[@b1] scan range, *m/z* 237--731. Regarding the latter, parameters were applied as follows: capillary voltage, −2.3 kV; cone voltage, −30 V; CE, −6 eV for MS and −30 to −70 eV for MS/MS, respectively; and MS[@b1] scan range, *m/z* 441--1251.

Post-acquisition data processing was automatically performed by UNIFI software (v.1.6.0, Waters), and MassLynx 4.1 software (Waters) was utilized for minor compound identification. An in-house library that contained the molecular formulae, molecular weights, and chemical structures of 389 compounds that were previously isolated from Ginseng Radix et Rhizoma (75 compounds), Astragali Radix (109 compounds), Glycyrrhiza Radix et Rhizoma (162 compounds), and Cinnamomi Cortex (43 compounds) was constructed to assist the chemical identification. Moreover, the retention times and mass spectral information, particular the DFIs of the authentic compounds, were also included in the in-house library.

UPLC/Qtrap-MS conditions for qualitative analysis
-------------------------------------------------

A Waters ACQUITY H-Class UPLC system (Milford, MA, USA) was connected online with an ABSciex 4500 Qtrap mass spectrometer (Foster City, CA, USA) *via* an ESI interface. The chromatographic separation program was identical to the method described above. An auto-sampler was responsible for triggering the mass spectrometer *via* a pulse signal.

In the mass domain, the ion source parameters were maintained as follows: polarity, negative; ion spray voltage, −4500 V; source temperature, 550 °C; curtain gas (CUR), 35 psi; ion source gas 1 (GS1), 55 psi; ion source gas 2 (GS2), 55 psi. The data acquisition and processing were performed by ABSciex Analyst 1.6.2 software. Some survey experiments, including pMRM mode, MIM mode, and Prec scan, were adopted to trigger EPI scans in the linear ion trap cell (scan rate, 20000 Da/s) through an IDA procedure to search for saponins and flavonoids.

The scanning programs for saponins were as follows:

### pMRM-EPI

pMRM-EPI procedures in the literature were used with minor modifications[@b57]. Two separate runs were performed with the mass ranges of *m/z* 441.5--843.5 and *m/z* 843.5--1255.5 for Q1. The dwell time was set to 8 ms for each ion transition. The IDA threshold and the CE of EPI were set to 500 cps and −65 ± 20 eV, respectively.

### MIM-EPI

Stepped MIM-EPI protocols developed in our previous study were implemented with minor modifications[@b58]. A total of 412 MIM transitions were fragmented into two separate runs from *m/z* 441.5--843.5 and *m/z* 843.5--1255.5 for Q1 with a step-size of 2 u. The dwell time was set to 8 ms for each transition. IDA threshold and CE of EPI were set at 500 cps and −65 ± 20 eV, respectively.

The scanning modes for flavonoids were as follows:

### MIM-EPI

Two separate runs were performed at the mass range of *m/z* 237.5--401.5 and *m/z* 401.5--727.5 for Q1, with a step-size of 2 u. The dwell time was set to 8 ms for each transition. The IDA threshold and the CE of EPI were set to 500 cps and −35 ± 15 eV, respectively.

### Prec-EPI

Prec scans of ions, including *m/z* 253, 255, 267, 269, 271, 283, 285, 289, 299, and 301, were performed using a fixed CE (−25 eV) in the scan range of *m/z* 237.5--727.5. The IDA threshold and CE of EPI were set to 2000 cps and −25 ± 15 eV, respectively.

UPLC/Qtrap-MS conditions for quantitative analysis
--------------------------------------------------

The large-scale semi-quantitation of 139 compounds and simultaneous absolute quantitation of 36 representative compounds in BYD were performed on a UPLC/Qtrap-MS system using sMRM mode. To shorten the analysis time while maintaining satisfactory separation, the gradient elution program was optimized as follows: 0--1.0 min, 2--10% B; 1.0--8.5 min, 10--25% B; 8.5--10.0 min, 25--29.5% B; 10.0--12.0 min, 29.5--30% B; 12.0--16.0 min, 30--40% B; 16.0--20.0 min, 40--60% B; 20.0--23.5 min, 60--100% B; 23.5--24.5 min, 100--100% B; 24.5--24.55 min, 100--2% B; 24.55--27.5 min, 2--2% B. Six batches of BYD lyophilized powders were prepared using the procedure described above. The accurately weighed lyophilized powders of each batch (0.2 g) were thoroughly suspended in ten volumes of 5% aqueous ACN. After centrifugation at 9,600 rpm for 10 min, the supernatant was filtered through a 0.22 μm membrane prior to LC-MS analysis. The injection volume and other LC conditions were set as previously described.

Each of the 36 analytes was prepared at a concentration of approximately 100 ng/mL with 50% aqueous ACN. They were directly infused into the ESI interface to investigate their optimal mass spectrometric parameters, including DPs and CEs. The ion transitions, corresponding *t*~R~, and optimal DPs and CEs of the sMRM scan mode are shown in [Table S3](#S1){ref-type="supplementary-material"}. The MRM detection window for each ion pair was set to 1.0 min, and the target scan time was set to 1.0s.

Preparation of stock and working solutions
------------------------------------------

To improve the quantitation precision and repeatability, baicalin was chosen as the internal standard (IS) for the determination of 11 flavonoids, and tenuifolin was used as the IS for 25 saponins ([Table S2](#S1){ref-type="supplementary-material"}).

Calibration curves
------------------

A mixed solution containing all 36 references was diluted to the appropriate concentrations using 50% aqueous ACN to construct calibration curves. At least six concentrations of the solution were analyzed in duplicate, and then calibration curves were generated to confirm the linearity between the ratio of the peak areas (analyte/IS) and the concentrations of the 36 analytes.

Assay validation of the scheduled MRM
-------------------------------------

The stock solutions were diluted to a series of appropriate concentrations with 50% aqueous methanol and were then injected into the LC-MS for analysis. The LODs and LOQs were determined as signal-to-noise ratios (S/N) of approximately 3 and 10, respectively. The repeatability of the method was determined by analyzing six replicates of a BYD sample and is represented as the relative standard deviation (RSD) of the content of each analyte. The intra- and inter-day variations were used to analyze the precision of the established method. For the intra-day variability test, six replicates of the same solution were analyzed on a single day, while for the inter-day variability test, the same solution was examined in triplicate on three consecutive days. The variations are expressed as the RSDs of the data. Stability tests were performed by analyzing the BYD sample solution over a period of 0 h, 2 h, 4 h, 8 h, 10 h, 12 h, and the RSD was used to evaluate the stability. Recovery tests were conducted on samples spiked with approximately 100% of known amounts of the analytes, with six replicates for each sample.
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![The workflow chart for global chemical profiling of *Baoyuan* decoction by integrated LC-MS strategy.](srep38379-f1){#f1}

![The sketch map of automated structural identification of components in *Baoyuan* decoction by UNIFI.\
The signals highlighted in blue are automatically identified according to MS data matching, whereas the signals tagged in blue automatically identified according to MS/MS data matching.](srep38379-f2){#f2}

![The extracted ion chromatograms (EICs) of references and BYD.\
(**A**) EIC of 36 ion transitions monitored under negative polarity for mixed references; (**B**) EIC of 36 ion transitions monitored under negative polarity for the BYD extract. The compound numbers are same as those described in [Table 2](#t2){ref-type="table"}.](srep38379-f3){#f3}

![The base peak chromatogram (BPC) of *Banyuan* decoction extract and MS^E^ spectra at 17.51 min by UPLC/Q-TOF-MS (**A**); Enhanced product ions (EPI) spectra of co-eluting ions at *m/z* 807.4 (**B**), 823.4 (**C**), 837.4 (**D**), 955.5 (**E**), 1077.6 (**F**), and 1209.6 (**G**) using IDA analysis mode of UPLC/Qtrap-MS.](srep38379-f4){#f4}

###### Characterization of the chemical constituents of *Baoyuan* decoction by UPLC/Q-TOF-MS.

  No.                 *t*~R~ (min)   \[M-H\]^−^   Error   \[M + COOH\]^−^   Error       Formula      Identification^a^
  ------------------ -------------- ------------ ------- ----------------- ------- ----------------- ------------------------------------------------------------------------------------------
  S~GU~-1^m^              9.5         839.408      1.9                              C~42~H~64~O~17~  Yunganoside G2
  S~GU~-2^m^             10.94        969.4682    −1.3                              C~48~H~74~O~20~  g-*O*-Rha-GlcA-GlcA
  S~GU~-3\*^C^            12.2        823.4131     1.8                              C~42~H~64~O~16~  Uralsaponin C
  S~GU~-4^m^             12.33        969.4682    −1.3                              C~48~H~74~O~20~  Albiziasaponin B
  S~GU~-5^m^             12.82       1027.4719     −3                               C~50~H~76~O~22~  g-*O*-Acetyl-GlcA-GlcA-Glc
  S~GU~-6^C^             12.97        835.3771     1.9                              C~42~H~60~O~17~  24-Hydroxyl-licorice E2/Yunganoside M
  S~GU~-7^m^             13.06        823.4142     3.2                              C~42~H~64~O~16~  Uralsaponin C
  S~GU~-8^m^              13.4        999.4434    −0.3                              C~48~H~72~O~22~  24-Hydroxy-licorice-saponin A3
  S~GU~-9\*^C^            13.5        895.3962    −0.2                              C~44~H~64~O~19~  Uralsaponin F
  S~GU~-10                13.6        821.3938    −2.7                              C~42~H~62~O~16~  Macedonoside C
  S~GU~−11^C^            13.68        853.3877     2.2                              C~42~H~62~O~18~  22-Hydroxy-licorice-saponin G2
  S~GU~-12^m^            14.07        851.4052    −1.8                              C~43~H~64~O~17~  Not identified
  S~GU~-13^m^            14.13        895.397      0.7                              C~44~H~64~O~19~  Isomer of uralsaponin F
  S~GU~-14^m^            14.17        953.4739    −0.7                              C~48~H~74~O~19~  d/e/f-*O*-Xyl(Ara)-GlcA-GlcA
  S~GU~-15^C^            14.38        823.4111    −0.6                              C~42~H~64~O~16~  Uralsaponin C
  S~GU~-16^m^             14.6       1011.4815     1.4                              C~49~H~74~O~19~  Licorice saponin D3
  S~GU~-17^C^              15         835.3748     0.4                              C~42~H~60~O~17~  24-Hydroxyl-licorice E2
  S~GU~-18^C^            15.01        849.3528    −2.2                              C~42~H~58~O~18~  Uralsapionin D
  S~GU~-19^m^            15.16        835.375     −0.2                              C~42~H~60~O~17~  Uralsaponin E
  S~GU~-20^C^            15.22       1025.4581    −1.8                              C~50~H~74~O~22~  Uralsaponin X
  S~GU~-21\*^C^          15.31        983.4489     0.1                              C~48~H~72~O~21~  Licorice-saponin A3
  S~GU~-22^m^            15.75        865.4229     0.8                              C~44~H~66~O~17~  22*β*-Acetoxyglycyrrhizic acid
  S~GU~-23\*^C^          15.87        879.402      0.5                              C~44~H~64~O~18~  22*β*-acetoxyglycyrrhizin
  S~GU~-24^m^            16.03        837.3928     2.3                              C~42~H~62~O~17~  Uralsaponin U/Uralsaponin N
  S~GU~-25^m^            16.26        969.4703     0.8                              C~48~H~74~O~20~  m/n-*O*-Xyl(Ara)-GlcA-GlcA
  S~GU~-26^m^             16.3        865.4229     0.8                              C~44~H~66~O~17~  22*β*-Acetoxy-licorice-saponin B2
  S~GU~-27^m^            16.37        969.4703     0.8                              C~48~H~74~O~20~  m/n-*O*-Xyl(Ara)-GlcA-GlcA
  S~GU~-28^C^            16.53        823.4131     0.3                              C~42~H~64~O~16~  Uralsaponin P
  S~GU~-29^m^            16.83        953.4752     0.6                              C~48~H~74~O~19~  Yunganoside H1
  S~GU~-30\*^C^           17.2        819.3803      0                               C~42~H~60~O~16~  Licorice-saponin E2
  S~GU~-31\*^C^          17.41        837.3895    −1.7                              C~42~H~62~O~17~  Licorice-saponin G2
  S~GU~-32^m^            17.51        807.4173     0.7                              C~42~H~64~O~15~  Yunganoside I2/Licorice saponin B2
  S~GU~-33^C^            17.53        823.4119     0.4                              C~42~H~64~O~16~  Uralsaponin P
  S~GU~-34^m^            17.75        837.3932     2.7                              C~42~H~62~O~17~  Uralsaponin U/Uralsaponin N
  S~GU~-35^C^            17.78        819.3813     1.2                              C~42~H~60~O~16~  Yunganoside E2
  S~GU~-36^m^              18         863.4068     0.3                              C~44~H~64~O~17~  22*β*-Acetoxyglycyrrhaldehyde
  S~GU~-37^m^            18.12        953.4752     0.6                              C~48~H~74~O~19~  Uralsaponin T
  S~GU~-38^m^             18.3        879.402      0.5                              C~44~H~64~O~18~  Uralsaponin M
  S~GU~-39^m^            18.39        865.4229     0.4                              C~42~H~62~O~17~  r-*O*-GlcA-Glc
  S~GU~-40^m^            18.48        793.4029     2.4                              C~41~H~62~O~15~  Not identified
  S~GU~-41^m^             18.5        967.4534    −0.1                              C~48~H~71~O~20~  Rhaoglycyrrhizin
  S~GU~-42^C^            18.66        837.3912     0.4                              C~42~H~62~O~17~  Uralsaponin U/Uralsaponin N
  S~GU~-43^m^            18.75        865.4225     0.3                              C~44~H~66~O~17~  22*β*-Acetoxy-licorice-saponin B2
  S~GU~-44\*^C^          19.01        821.4089    15.7                              C~42~H~62~O~16~  Glycyrrhizic acid
  S~GU~-45\*^C^          19.11        821.4089    15.7                              C~42~H~62~O~16~  Licorice-saponin H2
  S~GU~-46^m^            19.23        807.4173    −4.5                              C~42~H~64~O~15~  Glycyrflavoside C
  S~GU~-47^C^             19.7        807.4169     0.2                              C~42~H~64~O~15~  22-Dehydroxyl-uralsaponin C
  S~GU~-48^C^            20.01        807.4164    −0.4                              C~42~H~64~O~15~  Yunganoside I2
  S~GU~-49^m^            20.14        807.4161    −0.7                              C~42~H~64~O~15~  Yunganoside I2
  S~GU~-50^m^            20.39        821.3961     0.1                              C~42~H~62~O~16~  Licorice-saponin H2
  S~GU~-51^C^            20.79        821.3961     0.1                              C~42~H~62~O~16~  Isomer of licorice-saponin H2
  S~GU~-52^m^             21.1        777.4047    −1.8                              C~41~H~62~O~14~  d/e/f-*O*-GlcA-Glc
  S~GU~-53\*^C^          21.49        823.4103    −1.6                              C~42~H~64~O~16~  Licorice saponin J2
  S~GU~-54^C^             22.5        805.4028     2.2                              C~42~H~62~O~15~  Uralsaponin W
  S~GU~-55\*^C^          22.98        807.4167      0                               C~42~H~64~O~15~  Licorice-saponin B2
  S~GU~-56\*^m^          29.59        469.3318     0.4                              C~30~H~46~O~4~   Glycyrrhetic acid
  S~AM~-1^C^             15.02        945.5021     −4        991.5098       −1.6    C~47~H~78~O~19~  Astragaloside V
  S~AM~-2^C^              16.8        945.5045    −1.5       991.5098       −1.6    C~47~H~78~O~19~  Astragaloside VI
  S~AM~-3\*^C^            17.9                                829.458       −0.7    C~41~H~68~O~14~  Astragaloside III
  S~AM~-4\*^C^            18.1                                829.458       −0.7    C~41~H~68~O~14~  Astragaloside IV
  S~AM~-5\*^C^           19.77                               871.4691         0     C~43~H~70~O~15~  Astragaloside II
  S~AM~-6^C^             20.89                               871.4691         0     C~43~H~70~O~15~  Cyclogaleginoside D
  S~AM~-7\*^C^           21.92                               871.4691         0     C~43~H~70~O~15~  Isoastragaloside II
  S~AM~-8^C^             23.32                               913.4772       −2.5    C~45~H~72~O~16~  Astragaloside I
  S~AM~-9^C^             24.16                               913.4762       −1.5    C~45~H~72~O~16~  Isoastragaloside I
  S~AM~-10^C^            25.29                               913.4772       −2.5    C~45~H~72~O~16~  Cyclosieversioside B
  S~PG~-1^m^              2.79        979.5487    −3.5       1025.5474       3.5    C~44~H~84~O~23~  Q-*O*-Glc-Glc-Glc
  S~PG~-2^m^              3.61        961.5381    −4.5                              C~48~H~82~O~19~  Re1/Re2/Re3/20-glu-Rf/NotoginsenosideM/N/Vinaginsenoside R4
  S~PG~-3^m^              3.65        961.5349    −2.4       1007.5427        0     C~48~H~82~O~19~  Re1/Re2/Re3/20-glu-Rf/NotoginsenosideM/N/Vinaginsenoside R4
  S~PG~-4^m^              3.86        963.5538     0.9                              C~48~H~84~O~19~  Neoalsoside J1
  S~PG~-5^m^              5.22        961.5379     0.7                              C~48~H~82~O~19~  Gypenoside Gc7
  S~PG~-6^m^              7.02        961.5349    −2.4       847.5024       −3.7    C~48~H~82~O~19~  Re1/Re2/Re3/20-glu-Rf/NotoginsenosideM/N/Vinaginsenoside R4
  S~PG~-7^m^              7.27        801.5007     0.9       847.5024       −3.7    C~42~H~74~O~14~  Ginsenoside Rf2
  S~PG~-8^C^              7.71        931.5271     0.5       977.5328        0.7    C~47~H~80~O~18~  Re4/Notoginsenoside R1
  S~PG~-9^C^              7.74        961.5372      0                               C~48~H~82~O~19~  Re1/Re2/Re3/20-glu-Rf/NotoginsenosideM/N/Vinaginsenoside R4
  S~PG~-10^C^             8.39        931.5237    −0.4       977.5336        1.2    C~47~H~80~O~18~  Re4/Notoginsenoside R1
  S~PG~-11^m^             8.56        801.4427     0.2       847.4692        0.1    C~41~H~70~O~15~  Floralginsenoside C
  S~PG~-12^m^             8.9         961.5391    −1.3                              C~48~H~82~O~19~  Re1/Re2/Re3/20-glu-Rf/NotoginsenosideM/N/Vinaginsenoside R4
  S~PG~-13^m^             9.01        961.5372     −2                               C~48~H~82~O~19~  Re1/Re2/Re3/20-glu-Rf/NotoginsenosideM/N/Vinaginsenoside R4
  S~PG~-14\*^C^           9.2         799.4818    −3.3       845.4896       −0.4    C~42~H~72~O~14~  Ginsenoside Rg1
  S~PG~-15\*^C^           9.37        945.5444     2.2       991.5493        1.5    C~48~H~82~O~18~  Ginsenoside Re
  S~PG~-16^C^             9.4         799.4818    −3.3       845.4896       −0.4    C~42~H~72~O~14~  Ginsenoside Rg1
  S~PG~-17^m^             9.8         799.4863     2.4       845.4896       −0.4    C~42~H~72~O~14~  Isomer of ginsenoside Rg1
  S~PG~-18^m^            10.12        799.4863     2.4       845.4896       −0.4    C~42~H~72~O~14~  Isomer of ginsenoside Rg1
  S~PG~-19^m^            10.86        979.546     −1.8       1025.5508      −2.3    C~48~H~84~O~20~  Vinaginsenoside R13
  S~PG~-20^m^             10.9        987.5534      0                               C~50~H~84~O~19~  Acetyl-ginsenoside Re
  S~PG~-21^m^             11.5        915.533      1.4        961.537       −0.2    C~47~H~80~O~17~  J/K/L-*O-*Xyl(Ara)-Rha-Glc
  S~PG~-22^m^            11.63        987.5534      0                               C~50~H~84~O~19~  Acetyl-ginsenoside Re
  S~PG~-23^m^            12.56        915.5313     0.3       961.5377        0.5    C~47~H~80~O~17~  J/K/L-*O-*Glc-Rha-Xyl(Ara)
  S~PG~-24^m^            12.72       1125.6024    −2.9       1171.6058      −4.6    C~54~H~94~O~24~  P-*O-*Glc-Glc-Glc-Glc
  S~PG~-25^m^            13.09        987.5531     0.2       1033.5552       −3     C~50~H~84~O~19~  Acetyl-ginsenoside Re
  S~PG~-26^m^            13.56        961.533     −4.4                              C~48~H~82~O~19~  Re1/2/3, 20-glu-Rf, Notoginsenoside N
  S~PG~-27^C^              14         785.4659    −3.6                              C~41~H~70~O~14~  M/N/O-*O-*Glc-Xyl(Ara)
  S~PG~-28^m^            14.24        963.5531     0.2                              C~48~H~84~O~19~  Neoalsoside J1
  S~PG~-29\*^C^          14.46        799.4821    −2.9       845.4893       −0.7    C~42~H~72~O~14~  Ginsenoside Rf
  S~PG~-30\*^C^          14.57        799.4824    −2.5       845.4893       −0.7    C~42~H~72~O~14~  Pseudoginsenoside F11
  S~PG~-31\*^C^          15.24        769.4734    −0.5       815.4792       −0.1    C~41~H~70~O~13~  Notoginsenoside R2
  S~PG~-32^m^            15.99        637.4327     1.7       683.4374        0.6    C~36~H~62~O~9~   Ginsenoside Rh1
  S~PG~-33\*^C^          16.08        783.4918     2.3       829.4974         3     C~42~H~72~O~13~  Ginsenoside Rg2
  S~PG~-34^C^            16.38        783.4894    −0.1       829.4948       −0.1    C~42~H~72~O~13~  Isomer of ginsenoside Rg2
  S~PG~-35\*^C^           16.5        637.4327     1.7       683.4374        0.6    C~36~H~62~O~9~   Ginsenoside Rh1
  S~PG~-36^m^            16.77       1029.6227    −3.4       1255.6305      −1.4    C~58~H~98~O~26~  G/H-*O-*Glc-Glc-Glc-Xyl(Ara)-Xyl(Ara)
  S~PG~-37\*^C^          16.97       1107.5946    −0.5       1153.6022       1.4    C~54~H~92~O~23~  Ginsenoside Rb1
  S~PG~-38^m^            17.32       1149.6062     0.4       1195.6072      −3.3    C~56~H~94~O~24~  Quinquenoside R1
  S~PG~-39\*^C^          17.51        955.4901    −0.2                              C~48~H~76~O~19~  Ginsenoside Ro
  S~PG~-40\*^C^          17.51       1077.5848     0.3                              C~53~H~90~O~22~  Ginsenoside Rc
  S~PG~-41^C^            17.63       1209.6207     −5                               C~58~H~98~O~26~  Ginsenoside Ra1
  S~PG~-42^C^            17.88       1119.5918    −2.9       1165.5959       −4     C~55~H~92~O~23~  Ginsenoside Rs2
  S~PG~-43\*^C^          18.09       1077.5822     3.2       1123.5898      −0.2    C~53~H~90~O~22~  Ginsenoside Rb2
  S~PG~-44\*^C^          18.28       1077.5822    −2.5                              C~53~H~90~O~22~  Ginsenoside Rb3
  S~PG~-45^C^            18.37       1119.5936    −1.3       1165.5957      −4.2    C~55~H~92~O~23~  Ginsenoside Rs2
  S~PG~-46^C^            18.74       1149.6062     0.4       1195.6072      −3.3    C~56~H~94~O~24~  Quinquenoside R1
  S~PG~-47^m^             19.1        793.439       2                               C~42~H~66~O~14~  Chikusetsusaponin Iva/Zingibroside R1
  S~PG~-48\*^C^          19.23        945.5413    −1.1       991.5466       −1.2    C~48~H~82~O~18~  Ginsenoside Rd
  S~PG~-49^C^            19.25       1119.5918    −2.9       1165.5959       −4     C~55~H~92~O~23~  Ginsenoside Rs2
  S~PG~-50^m^            19.53        987.5536     0.7       1033.5531       −5     C~50~H~84~O~19~  Pseudoginsenoside Rc1
  S~PG~-51^m^            19.54       1031.5437      1                               C~51~H~84~O~21~  Malonyl-Ginsenoside Rd
  S~PG~-52^C^            19.54        945.5413    −1.1       991.5466       −1.2    C~48~H~82~O~18~  Isomer of ginsenoside Rd
  S~PG~-53^m^            19.73        987.5536     0.7       1033.5531       −5     C~50~H~84~O~19~  Pseudoginsenoside Rc1
  S~PG~-54^C^            19.77        945.5413    −1.1       991.5466       −1.2    C~48~H~82~O~18~  Isomer of ginsenoside Rd
  S~PG~-55^C^            19.79       1119.5936    −1.3       1165.5957      −4.2    C~55~H~92~O~23~  Ginsenoside Rs2
  S~PG~-56^C^            20.17        945.5433     1.1       991.5486        0.8    C~48~H~82~O~18~  Gypenoside XVII
  S~PG~-57^C^            20.35        987.5536     0.7       1033.5531       −5     C~50~H~84~O~19~  Pseudoginsenoside Rc1
  S~PG~-58^m^            20.75        915.5294    −0.3       961.5387        1.6    C~47~H~80~O~17~  G/H-*O-*Glc-Glc-Xyl(Ara)
  S~PG~-59^C^            21.19        987.5536     0.7       1033.5531       −5     C~50~H~84~O~19~  Pseudoginsenoside Rc1
  S~PG~-60^m^            21.25        751.4615    −2.4                              C~41~H~68~O~12~  Notoginsenoside T5
  S~PG~-61^m^            21.75        751.4645     1.6                              C~41~H~68~O~12~  Notoginsenoside T5
  S~PG~-62\*^C^          21.79        765.4765    −3.1       811.4833       −1.4    C~42~H~70~O~12~  Ginsenoside Rg6
  S~PG~-63\*^C^          22.27        765.4797      1        811.4847        0.4    C~42~H~70~O~12~  Ginsenoside F4
  S~PG~-64^C^            23.04        783.4885    −1.3       829.4949         0     C~42~H~72~O~13~  Isomer of ginsenoside Rg3
  S~PG~-65^m^             23.5        793.4382      1                               C~42~H~66~O~14~  Chikusetsusaponin Iva/Zingibroside R1
  S~PG~-66\*^C^           24.4        783.4885    −1.3       829.4949         0     C~42~H~72~O~13~  Ginsenoside Rg3
  S~PG~-67^C^            24.72        783.4885    −1.3       829.4949         0     C~42~H~72~O~13~  Isomer of ginsenoside Rg3
  S~PG~-68\*^C^          27.55        765.4778    −1.4       811.4836        −1     C~42~H~70~O~12~  Ginsenoside Rk1
  S~PG~-69\*^C^          27.88        765.4782    −0.9       811.4824       −2.5    C~42~H~70~O~12~  Ginsenoside Rg5
  S~PG~-70^m^              28         807.485     −4.5                              C~44~H~72~O~13~  Ginsenoside Rs4/Rs5
  S~PG~-71^m^             28.2        621.4378     1.9       667.4397       −3.6    C~36~H~62~O~8~   Ginsenoside Rh2
  S~PG~-72 \*^m^         28.41        621.4396     4.8       667.4421         0     C~36~H~62~O~8~   Ginsenoside Rh2
  S~PG~-73^m^            29.57        807.4892    −0.4       853.4925       −2.8    C~44~H~72~O~13~  Ginsenoside Rs4/Rs5
  F~AM~-8^m^              6.4         595.1461     1.5                              C~27~H~32~O~15~  5/8-Hydroxy-liquiritigenin-*O*-diglucoside or 8-Hydroxy-liquiritigenin-*O*-diglucoside
  F~AM~-13^C^             7.46        461.1081    −0.7                              C~22~H~22~O~11~  Isomer of 5′-hydroxy-4′-methoxyisoflavone-3′-*β*-d-glucoside
  F~AM~-36\*^m^            10         595.2013    −2.4                              C~28~H~36~O~14~  Isomucronulatol-2′-*O*-*β*-d-apiosyl(1 → 2)-*β*-d-glucoside
  F~AM~-38^m^            10.82        431.0975    −0.7                              C~21~H~20~O~10~  5,7-Dihydroxyl-flavone-4′-*O*-glucoside
  F~AM~-40^m^            11.21        461.1069    −3.3                              C~22~H~22~O~11~  Isomer of 5′-hydroxy-4′-methoxyisoflavone-3′-*β*-d-glucoside
  F~AM~-41^m^            11.25        445.1124    −2.5       491.1194        0.8    C~22~H~22~O~10~  Isomer of calycosin-7-*O*-*β*-d-glucoside
  F~AM~-43^m^            11.44        625.2121    −1.8                              C~29~H~38~O~15~  Isomucronulatol-*O*-diglucoside
  F~AM~-47^m^             11.6        447.1281    −2.2                              C~22~H~24~O~10~  5-Hydroxy-7-methoxyflavanone-5-*O*-glucoside
  F~AM~-49^m^             12.1        463.1617     2.8       509.1708       −0.1    C~23~H~28~O~10~  Isomucronulatol-7-*O*-*β*-d-glucoside
  F~AM~-50^m^            12.28        433.1477    −3.4                              C~22~H~26~O~9~   Isomucronulatol-*O*-apioside
  F~AM~-54^m^             12.8        253.0498    −0.12                             C~15~H~10~O~4~   Isomer of 7,4′-dihydroxyflavone
  F~AM~-60^m^             13.3        463.1617     2.8       509.1708       −0.1    C~23~H~28~O~10~  Isomucronulatol-7-*O*-*β*-d-glucoside
  F~AM~-62^m^             13.6        283.0607    −0.1                              C~16~H~12~O~5~   Isomer of calycosin
  F~AM~-64\*^m^           13.7        253.0498    −0.12                             C~15~H~10~O~4~   7,4′-Dihydroxyflavone
  F~AM~-67^m^            13.91        471.1291    −0.6        517.134       −1.1    C~24~H~24~O~10~  Acetyl-ononin
  F~AM~-68^m^             14.2        283.0616    −3.6                              C~16~H~12~O~5~   Isomer of calycosin
  F~AM~-69^m^            14.22        579.1721     1.2                              C~27~H~32~O~14~  Liquiritigenin/Isoliquiritigenin-*O*-diglucoside
  F~AM~-70^m^            14.23        593.1862    −1.3                              C~28~H~34~O~14~  9,10-Dimethoxy-pterocarpane-3-*O*-glucoside-apioside
  F~AM~-71^m^            14.47        593.1862    −1.3                              C~28~H~34~O~14~  3,9-Dimethoxy-pterocarpane-10-*O*-glucoside-apioside
  F~AM~-72^C^            15.07        463.1617     2.8       509.1708       −0.1    C~23~H~28~O~10~  Isomucronulatol-7-*O*-*β*-d-glucoside
  F~AM~-75\*^C^          15.22        283.0607    −0.1                              C~16~H~12~O~5~   Calycosin
  F~AM~-76\*^C^           15.7        463.1617     2.8       509.1708       −0.1    C~23~H~28~O~10~  (3 *R*)-(+)-isomucronulatol-2′-*O*-*β*-d-glucoside
  F~AM~-77^m^            17.87        269.0451     0.4                              C~15~H~10~O~5~   Resokaempferol
  F~AM~-78^m^             18.3        299.0562      1                               C~16~H~12~O~6~   Isomer of pratensein
  F~AM~-79^m^             18.9        299.0899                                      C~17~H~16~O~5~   3-Hydroxy-9,10-dimethoxy-pterocarpane
  F~AM~-80^m^            19.01        299.0899      1                               C~17~H~16~O~5~   10-Hydroxy-3,9-dimethoxy-pterocarpane
  F~AM~-81^C^            19.09        253.0498    −0.12      299.0567        3.7    C~15~H~10~O~4~   Isomer of 7,4′-dihydroxyisoflavone
  F~AM~-82\*^C^          20.25        267.0658     0.4                              C~16~H~12~O~4~   Formononetin
  F~CC~-3^C^              4.97        289.0727     4.1                              C~15~H~14~O~6~   Catechin or Epicatechin
  F~CC~-9^C^              6.65        289.072      3.1                              C~15~H~14~O~6~   Catechin or Epicatechin
  F~CC~-11^m^             6.69        289.0727     4.1                              C~15~H~14~O~6~   Catechin or Epicatechin
  F~GU,AM~-25\*^C^        8.95        445.1125    −2.3       491.1192         0     C~22~H~22~O~10~  Calycosin-7-*O*-*β*-d-glucoside
  F~GU,AM~-51^m^          12.3        561.1617     1.6                              C~27~H~30~O~13~  Isomer of ononin-*O*-apioside
  F~GU,AM~-55^m^           13         561.1617     1.6                              C~27~H~30~O~13~  Isomer of ononin-*O*-apioside
  F~GU~-2^m^              3.95        661.178      2.3                              C~32~H~34~O~16~  Isomer of liquiritigenin-*O*-diglucoside
  F~GU~-4^m^              5.7         499.1238    −1.2                              C~25~H~24~O~11~  Isomer of liquiritin
  F~GU~-5^m^              5.87        499.1248     0.9                              C~25~H~24~O~11~  Isomer of liquiritin apioside
  F~GU~-6^m^              5.88        631.167       1                               C~30~H~32~O~15~  Isomer of liquiritin apioside
  F~GU~-7^C^              6.18        579.1732     3.1       625.1782        2.1    C~27~H~32~O~14~  Isomer of liquiritigenin-*O*-diglucoside
  F~GU~-10^m^             6.65        711.2163     2.7                              C~32~H~40~O~18~  Isomer of liquiritin-*O*-glucoside
  F~GU~-12\*^C^           7.21        593.1513     1.2                              C~27~H~30~O~15~  Apigenin-6,8-di-*C*-*β*-d-glucopyranoside
  F~GU~-14^m^             7.66        415.1016    −2.9                              C~21~H~20~O~9~   Daidzein-7-O-galactoside
  F~GU~-15^m^             7.7         595.166     −0.5       641.1732        2.2    C~27~H~32~O~15~  5-Hydroxy-liquiritigenin-*O*-diglucoside or 8-Hydroxy-liquiritigenin-*O*-diglucoside
  F~GU~-16^C^             8.1         563.1408     1.2                              C~26~H~28~O~14~  Isoschaftoside
  F~GU~-17^C^             8.2         579.1732     3.1                              C~27~H~32~O~14~  Liquiritigenin-*O*-diglucoside
  F~GU~-18^m^             8.34        711.2163     2.7                              C~32~H~40~O~18~  5-Dihydroxy-liquiritigenin-*O*-diglucoside or 8-Dihydroxy-liquiritigenin-*O*-diglucoside
  F~GU~-19^m^             8.41        415.1016    −2.9                              C~21~H~20~O~9~   Daidzein-7-*O*-galactoside
  F~GU~-20^m^             8.42        547.1432    −2.4                              C~26~H~28~O~13~  Liquiritin/Isoliquiritin-*O*-apioside
  F~GU~-21^m^             8.64        711.2163     2.7                              C~32~H~40~O~18~  5-Dihydroxy-liquiritigenin-*O*-diglucoside or 8-Dihydroxy-liquiritigenin-*O*-diglucoside
  F~GU~-22^m^             8.75        547.1432    −2.4                              C~26~H~28~O~13~  Liquiritin/Isoliquiritin-*O*-apioside
  F~GU~-23^C^             8.75        433.1129    −1.4                              C~21~H~22~O~10~  5-Hydroxy-liquiritin or 8-Hydroxy-liquiritin
  F~GU~-24^C^             8.82        579.1732     3.1                              C~27~H~32~O~14~  Liquiritigenin-*O*-diglucoside
  F~GU~-26\*^C^           8.96        417.1188     0.5                              C~21~H~22~O~9~   Neoisoliquiritin
  F~GU~-27^C^              9          579.1732     3.1                              C~27~H~32~O~14~  Liquiritigenin-*O*-diglucoside
  F~GU~-28^m^             9.01        433.1135      0                               C~21~H~22~O~10~  5-Hydroxy-liquiritin or 8-Hydroxy-liquiritin
  F~GU~-29^C^             9.02        549.1609     0.2                              C~26~H~30~O~13~  Neoliquiritin-*O*-apioside
  F~GU~-30\*^C^           9.11        417.1187     0.2                              C~21~H~22~O~9~   Liquiritin
  F~GU~-31\*^C^           9.4         549.1609     0.2                              C~26~H~30~O~13~  Liquiritin apioside
  F~GU~-32^m^             9.51        447.1308     3.1                              C~22~H~24~O~10~  2′-Hydroxy-7-methoxyflavanone-5-*O*-glucoside
  F~GU~-33^C^             9.61        577.1555     0.7                              C~27~H~30~O~14~  Isoviolanthin/Violanthin
  F~GU~-34^m^             9.7         565.1555    −0.4                              C~26~H~30~O~14~  7,8-Dihydroxyl-flavanone-4′-*O*-*β*-d-apiofuranosyl(1′ → 2″)-*O*-glucoside
  F~GU~-35^m^             9.7         447.1304     2.9                              C~22~H~24~O~10~  5-Hydroxy-7-methoxyflavanone-5-*O*-glucoside
  F~GU~-37^m^             10.6        417.1187     0.2                              C~21~H~22~O~9~   Isomer of liquiritin
  F~GU~-39^m^              11         447.1294     1.2                              C~22~H~24~O~10~  Genistin
  F~GU~-42^m^            11.25        447.1307      3                               C~22~H~24~O~10~  5-Hydroxy-7-methoxyflavanone-5-*O*-glucoside
  F~GU~-44^m^            11.48        565.1575     3.2                              C~26~H~30~O~14~  7,8-Dihydroxyl-flavanone-4′-*O*-*β*-d-apiofuranosyl(1′ → 2″)-*O*-glucoside
  F~GU~-45^C^            11.48        433.1127    −1.8                              C~21~H~22~O~10~  5-Hydroxy-liquiritin or 8-Hydroxy-liquiritin
  F~GU~-46^m^             11.5        579.1711    −0.3                              C~27~H~32~O~14~  Isomer of liquiritigenin-*O*-diglucoside
  F~GU~-48^m^             11.9        549.1609     0.2                              C~26~H~30~O~13~  Liquiritin apioside
  F~GU~-52^m^             12.4        431.1345    −0.7                              C~22~H~23~O~9~   Genistin
  F~GU~-53^m^            12.75        445.1124    −2.5       491.1194        0.8    C~22~H~22~O~10~  Isomer of calycosin-7-*O*-*β*-d-glucoside
  F~GU~-56^m^              13         579.1721     1.2                              C~27~H~32~O~14~  Isomer of isoliquiritigenin-*O*-diglucoside
  F~GU~-57\*^C^           13.1                               475.1263        2.3    C~22~H~22~O~9~   Ononin
  F~GU~-58^m^             13.1        591.1698    −2.7                              C~28~H~32~O~14~  Acetyl-isoliquiritin-*O*-apioside
  F~GU~-59\*^C^          13.21        549.1609     0.2                              C~26~H~30~O~13~  Isoliquiritin apioside
  F~GU~-61\*^C^           13.5        417.1187     0.2                              C~21~H~22~O~9~   Isoliquiritin
  F~GU~-63^m^            13.63        459.1301      2                               C~23~H~24~O~10~  Acetyl-liquiritin/isoliquiritin
  F~GU~-65\*^C^          13.81        549.1609     0.2                              C~26~H~30~O~13~  Licuraside
  F~GU~-66\*^C^           13.9        255.0656    −0.4                              C~15~H~12~O~4~   Liquiritigenin
  F~GU~-73^m^            15.13        433.151      2.5                              C~22~H~26~O~9~   5-Hydroxy-liquiritin or 8-Hydroxy-liquiritin
  F~GU~-74^m^            15.20        695.1835    −1.3                              C~31~H~36~O~18~  Liquiritigenin/Isoliquiritigenin-*O*-Glc-Api-Rha
  F~GU~-79^m^            18.56         459.13       2                               C~23~H~24~O~10~  Acetyl-Liquiritin/Isoliquiritin
  F~GU~-83\*^C^          20.26        255.0656    −0.4                              C~15~H~12~O~4~   Isoliquiritigenin
  P~CC~-1^C^              2.98        577.1349    −0.3                              C~30~H~26~O~16~  PAC B-type dimer
  P~CC~-2^C^              3.73        577.1353     0.2                              C~30~H~26~O~16~  PAC B-type dimer
  P~CC~-3^C^              4.14        577.1343    −1.4                              C~30~H~26~O~16~  PAC B-type dimer
  P~CC~-4^C^              4.54        577.1347    -0.7                              C~30~H~26~O~16~  PAC B-type dimer
  P~CC~-5^C^              5.07        577.1345    −0.9                              C~30~H~26~O~16~  PAC B-type dimer
  P~CC~-6^C^              6.46        865.2001     1.5                              C~45~H~38~O~18~  PAC B-type trimer
  L~CC~-1^C^              6.02        653.2457     0.9                              C~31~H~42~O~15~  Isolariciresinol-4-*O*-*β*-d-apiosyl (1 → 2)-*β*-d-glucoside
  L~CC~-2^C^              6.05        653.2453     1.3                              C~31~H~42~O~15~  Isolariciresinol-3′-*O*-*β*-d-apiosyl (1 → 2)-*β*-d-glucoside
  L~CC~-3^C^              6.29        551.2119    −2.7                              C~27~H~36~O~12~  5-Methoxy-isolariciresinol-4-*O*-*β*-d-glucoside
  L~CC~-4^C^              6.39        521.2019    −0.8                              C~26~H~34~O~11~  Isolariciresinol-4-*O*-*β*-d-glucoside
  D~CC~-1^C^              3.04        543.2439    −0.2                              C~26~H~40~O~12~  Cinncaside
  D~CC~-2\*^C^            3.85        365.1955    −0.9                              C~20~H~30~O~6~   Anhydrocinnzeylanol
  D~CC~-3\*^C^            4.51        425.2178     0.3                              C~22~H~34~O~8~   Cinnzeylanine
  D~CC~-4\*^C^            9.10        407.2014    −0.7                              C~22~H~32~O~7~   Anhydrocinnzeylanine

Notes \*: the compound identified by comparison with the reference.

^a^: the single English alphabet in capital or in lowercase means the aglycone in [Fig. S5](#S1){ref-type="supplementary-material"}.

^C^: the compound identified by UNIFI.

^m^: the compound detected by multiple screening modes of Qtrap-MS.

F: flavonoid; S: saponin; P: procyanidin; L: lignan; D: diterpene.

~AM~: the compound originated from *A. membranceus*; ~GU~: the compound originated from *G. uralensis*; ~PG~: the compound originated from *P. ginseng*; and ~CC~: the compound originated from *C. cassia*.

###### The contents (mg/g) of 36 investigated compounds in six batches of BYD extracts.

  No.   Analytes                                     Batch 1 (mg/g)   Batch 2 (mg/g)   Batch 3 (mg/g)   Batch 4 (mg/g)   Batch 5 (mg/g)   Batch 6 (mg/g)
  ----- ------------------------------------------- ---------------- ---------------- ---------------- ---------------- ---------------- ----------------
  1     Apigenin-6,8-di-*C*-*β*-d-glucopyranoside        38.79            35.78            37.85            38.79            39.85            35.67
  2     Calycosin-7-*O*-*β*-d-glucoside                  93.47            89.45            95.62            91.48            93.33            95.68
  3     Liquiritin                                       160.86           159.86           168.86           165.86           161.86           169.86
  4     Liquiritin aposide                               567.75           534.65           558.68           561.83           568.70           578.01
  5     Isoliquiritin aposide                            147.46           153.43           133.71           149.48           162.72           156.80
  6     Ginsenoside Rg1                                  521.08           500.76           489.19           499.81           473.48           514.48
  7     Ginsenoside Re                                   542.16           557.93           572.29           583.85           572.33           589.62
  8     Isoliquiritin                                    249.15           265.10           235.58           269.19           258.59           261.74
  9     Liquiritigenin                                   74.41            68.23            64.53            80.42            76.53            74.57
  10    Ononin                                           104.94           114.92           125.13           118.95           107.13           115.19
  11    Calycosin                                        129.62           138.59           131.84           125.63           133.85           141.2
  12    Uralsaponin C                                    167.29           153.51           149.32           169.2            163.75           159.42
  13    Uralsaponin F                                    131.85           132.03           128.88           139.78           121.43           127.96
  14    Licorice saponin A3                              31.85            29.03            30.88            32.78            31.43            32.96
  15    Ginsenoside Rf                                   98.64            90.77            104.66           101.59           93.32            97.72
  16    22*β*-Acetoxyglycyrrhizin                        279.58           283.97           285.65           269.43           281.67           273.81
  17    Ginsenoside Rg2                                  554.16           572.93           549.29           569.85           567.33           583.62
  18    Ginsenoside Rh1                                  15.80            13.50            16.10            154.00           14.80            14.10
  19    Ginsenoside Rb1                                  785.87           771.93           769.05           791.45           778.37           786.50
  20    Licorice saponin E2                              159.97           151.19           149.01           161.89           163.47           153.10
  21    Licorice saponin H2                               9.67             8.99             9.32             9.69             9.78            10.01
  22    Ginsenoside Rc                                   349.33           352.81           357.41           361.14           347.20           359.62
  23    Licorice saponin G2                              83.78            88.90            84.80            87.73            86.50            82.85
  24    Isoliquiritigenin                                 6.14             6.63             6.54             5.92             5.76             6.06
  25    Ginsenoside Ro                                   710.57           718.55           697.73           717.18           725.28           712.16
  26    Ginsenoside Rb2                                  210.32           202.61           193.37           219.21           222.64           213.50
  27    Formononetin                                     51.79            54.78            49.88            52.83            58.88            53.91
  28    Ginsenoside Rb3                                  42.14            40.82            42.95            41.18            42.93            39.85
  29    Ginsenoside Rg3                                  279.16           572.93           549.29           569.85           567.33           583.62
  30    Ginsenoside Rd                                   90.21            85.34            99.23            101.15           84.90            95.28
  31    Astragaloside II                                 194.92           205.20           214.97           197.81           221.27           215.09
  32    Isoastragaloside II                              87.33            90.95            86.54            91.37            88.34            86.39
  33    Glycyrrhizinic acid                              529.06           517.78           533.18           549.77           558.36           530.49
  34    Ginsenoside F4                                   25.23            24.71            23.94            26.25            24.99            27.14
  35    Astragaloside IV                                 702.02           691.91           689.80           711.72           703.45           709.86
  36    Ginsenoside Rg5                                  46.23            42.79            47.19            49.12            43.27            46.29

[^1]: These authors contributed equally to this work.
